A nationwide shortage of BCG vaccines in the country leaves Kenyan newborns vulnerable to TB, a disease with a high ...

A new tuberculosis vaccine that self-destructs to enhance safety has shown promising results in macaque monkeys, providing ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain ...

Scientists have developed a breakthrough mechanism that makes the intravenous Bacillus Calmette-Guérin (BCG) tuberculosis ...

Intravenous BCG vaccine with a built-in kill-switch was found to be at least as effective as regular tuberculosis vaccine in protecting monkeys against infection.

A self-destructing vaccine administered intravenously provides additional safety and protection against tuberculosis (TB) in ...

A new study published in the Journal of Internal Medicine showed that it may be possible to prevent the formation of ...

An experimental tuberculosis (TB) vaccine with a dual mission – self-destruction after inducing immunity – improved the design of the Bacillus Calmette-Guérin (BCG) immunotherapy, a vaccine also used ...

A self-destructing vaccine administered intravenously provides additional safety and protection against tuberculosis (TB) in macaque monkeys, suggests new University of Pittsburgh research published ...

Kenya has completely run out of essential medical supplies—including HIV medicines, testing kits, and vaccines—putting ...

Bacillus Calmette-Guérin (BCG) vaccine -- named for its developers -- contains inactivated mycobacteria that infect cattle and remains the only vaccination strategy against the infection in humans.